Trial Profile
Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Acronyms KIRMONO
- Sponsors Innate Pharma
- 05 Mar 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met, according to an Innate Pharma media release.
- 11 Dec 2012 Results have been reported in an Innate Pharma media release.
- 11 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.